| Trial ID: | L0441 |
| Source ID: | NCT03923933
|
| Associated Drug: |
Chlorthalidone
|
| Title: |
Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT03923933/results
|
| Conditions: |
Renal Insufficiency, Chronic
|
| Interventions: |
DRUG: Chlorthalidone|DRUG: Bumetanide
|
| Outcome Measures: |
Primary: Change in Total Body Water, Measured by bioelectrical impedance analysis, compared to the initial measurement, Change from Basal to day 28 | Secondary: Change in Mean Arterial Pressure, decrease in blood pressure compared wit baseline measure (mmhg), Change from Basal to day 28|Change in the Fractional Excretion of Sodium, Increase in the fractional excretion of sodium compared with the baseline measure, Change from Basal to day 28|Change in Extracellular Water, Decrease in extracellular water measured by bioelectrical impedance analysis, Change from Basal to day 28|Change in Extracellular Water / Total Body Water Ratio, Decrease in extracellular water / total body water ratio measured by bioelectrical impedance analysis, Change from Basal to day 28|Change in Systolic Blood Pressure, Change from Basal to day 28|Change in Diastolic Blood Pressure, Change from Basal to day 28
|
| Sponsor/Collaborators: |
Sponsor: Hospital General de México Dr. Eduardo Liceaga
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
34
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2019-06-18
|
| Completion Date: |
2019-10-28
|
| Results First Posted: |
2020-03-10
|
| Last Update Posted: |
2020-11-23
|
| Locations: |
Hospital General de Mexico, Mexico City, 06720, Mexico
|
| URL: |
https://clinicaltrials.gov/show/NCT03923933
|
